The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Therapeutic Advances in Psychopharmacology Pub Date : 2023-01-01 DOI:10.1177/20451253231172254
Ricarda Evens, Marianna Elisa Schmidt, Tomislav Majić, Timo Torsten Schmidt
{"title":"The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.","authors":"Ricarda Evens,&nbsp;Marianna Elisa Schmidt,&nbsp;Tomislav Majić,&nbsp;Timo Torsten Schmidt","doi":"10.1177/20451253231172254","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided. These transient effects, sometimes labeled as the 'psychedelic afterglow', have been suggested to be associated with enhanced effectiveness of psychotherapeutic interventions in the subacute period.</p><p><strong>Objectives: </strong>This systematic review provides an overview of subacute effects of psychedelics.</p><p><strong>Methods: </strong>Electronic databases (MEDLINE, Web of Science Core Collection) were searched for studies that assessed the effects of psychedelics (LSD, psilocybin, DMT, 5-MeO-DMT, mescaline, or ayahuasca) on psychological outcome measures and subacute adverse effects in human adults between 1950 and August 2021, occurring between 1 day and 1 month after drug use.</p><p><strong>Results: </strong>Forty-eight studies including a total number of 1,774 participants were eligible for review. Taken together, the following subacute effects were observed: reductions in different psychopathological symptoms; increases in wellbeing, mood, mindfulness, social measures, spirituality, and positive behavioral changes; mixed changes in personality/values/attitudes, and creativity/flexibility. Subacute adverse effects comprised a wide range of complaints, including headaches, sleep disturbances, and individual cases of increased psychological distress.</p><p><strong>Discussion: </strong>Results support narrative reports of a subacute psychedelic 'afterglow' phenomenon comprising potentially beneficial changes in the perception of self, others, and the environment. Subacute adverse events were mild to severe, and no serious adverse events were reported. Many studies, however, lacked a standardized assessment of adverse effects. Future studies are needed to investigate the role of possible moderator variables and to reveal if and how positive effects from the subacute window may consolidate into long-term mental health benefits.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240558/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253231172254","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided. These transient effects, sometimes labeled as the 'psychedelic afterglow', have been suggested to be associated with enhanced effectiveness of psychotherapeutic interventions in the subacute period.

Objectives: This systematic review provides an overview of subacute effects of psychedelics.

Methods: Electronic databases (MEDLINE, Web of Science Core Collection) were searched for studies that assessed the effects of psychedelics (LSD, psilocybin, DMT, 5-MeO-DMT, mescaline, or ayahuasca) on psychological outcome measures and subacute adverse effects in human adults between 1950 and August 2021, occurring between 1 day and 1 month after drug use.

Results: Forty-eight studies including a total number of 1,774 participants were eligible for review. Taken together, the following subacute effects were observed: reductions in different psychopathological symptoms; increases in wellbeing, mood, mindfulness, social measures, spirituality, and positive behavioral changes; mixed changes in personality/values/attitudes, and creativity/flexibility. Subacute adverse effects comprised a wide range of complaints, including headaches, sleep disturbances, and individual cases of increased psychological distress.

Discussion: Results support narrative reports of a subacute psychedelic 'afterglow' phenomenon comprising potentially beneficial changes in the perception of self, others, and the environment. Subacute adverse events were mild to severe, and no serious adverse events were reported. Many studies, however, lacked a standardized assessment of adverse effects. Future studies are needed to investigate the role of possible moderator variables and to reveal if and how positive effects from the subacute window may consolidate into long-term mental health benefits.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
致幻剂余辉现象:经典5 -羟色胺致幻剂亚急性效应的系统回顾。
背景:据报道,经典的5 -羟色胺类致幻剂在急性作用消退后仍具有亚急性作用的特征模式。这些短暂的效应,有时被称为“迷幻余辉”,被认为与亚急性期心理治疗干预的有效性增强有关。目的:本综述综述了致幻剂的亚急性作用。方法:检索电子数据库(MEDLINE, Web of Science Core Collection),以评估迷幻药(LSD、裸盖菇素、DMT、5-MeO-DMT、美斯卡林或死藤水)对1950年至2021年8月期间成人心理结局测量和亚急性不良反应的影响,这些不良反应发生在用药后1天至1个月内。结果:48项研究包括1,774名参与者符合审查条件。总的来说,观察到以下亚急性效应:不同精神病理症状的减轻;幸福感、情绪、专注力、社交能力、灵性和积极行为改变的增加;个性/价值观/态度和创造力/灵活性的混合变化。亚急性不良反应包括各种各样的症状,包括头痛、睡眠障碍和个体心理困扰增加。讨论:结果支持亚急性迷幻“余辉”现象的叙述性报道,该现象包括对自我、他人和环境感知的潜在有益变化。亚急性不良事件从轻度到重度不等,未见严重不良事件的报道。然而,许多研究缺乏对不良反应的标准化评估。未来的研究需要调查可能的调节变量的作用,并揭示亚急性窗口的积极影响是否以及如何巩固为长期的心理健康益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
期刊最新文献
Use of an injection of aripiprazole given once every 2 months (Abilify Asimtufii®) in people with bipolar I disorder: a Plain Language Summary of Publication. Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand. Low-frequency repetitive transcranial magnetic stimulation for the treatment of post-traumatic stress disorder and its comparison with high-frequency stimulation: a systematic review and meta-analysis. Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia. Incorporation of a specialist mental health clinical pharmacist within a primary care network: patient referrals, prescribing decisions, and clinical outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1